BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:In light of Anavex's announcement of its first entire clinical
  gene pathway data in patients with Rett syndrome\, coupled with Mission 
 Therapeutics' recent fundraising of £25.2 million to progress the clinica
 l development of its lead drug candidates\, there has been increasing evi
 dence of interest taking place towards broader disease groups with underl
 ying pathogenesis from mitochondrial dysfunction.\n\nThis November\, we w
 ill unite 60+ C-Level\, Biologist\, Preclinical\, Translational\, and Inn
 ovation-Scouting Leaders who are building on from the industry's latest s
 etbacks to innovate mitochondrial-targeting approaches and expand novel t
 herapeutic opportunities. From cutting-edge research backed by academia t
 o transformative pipeline updates from preclinical and clinical settings 
 revealed by the industry\, this is your chance to get involved and de-ris
 k clinical development by discovering and validating biomarkers for defin
 ed endpoints.\n\nURLs:Website:&nbsp\;https://go.evvnt.com/2562504-0?pid=1
 85Brochure:&nbsp\;https://go.evvnt.com/2562504-2?pid=185Tickets:&nbsp\;ht
 tps://go.evvnt.com/2562504-3?pid=185\n\nPrices:Drug Developer Pricing - C
 onference + Workshop Day: USD 3497.00\,Drug Developer Pricing - Conferenc
 e Only: USD 2599.00\,Not-for-Profit\, Academic\, Start-Up Pricing - Confe
 rence + Workshop Day: USD 2897.00\,Not-for-Profit\, Academic\, Start-Up P
 ricing - Conference Only: USD 2199.00\,Service Provider Pricing - Confere
 nce + Workshop Day: USD 4297.00\,Service Provider Pricing - Conference On
 ly: USD 3199.00\n\nSpeakers:&nbsp\;Amy Chadwick\, Professor\, University 
 of Liverpool\, Baerbel Rohrer\, Chief Executive Officer\, MitoChem Therap
 eutics\, Baruch Harris\, Chief Operating Officer\, Pretzel Therapeutics\,
  Brad Hubbard\, Assistant Professor\, University of Kentucky\, Christophe
 r Missling\, President and Chief Executive Officer\, Anavex\, Cynthia Arb
 eeny\, Chief Scientific Officer\, Mitotherapeutix\, Dima Martini-Drew\, G
 lobal Early Stage Medical Affairs Lead\, Astellas Pharma\, Enchi Liu\, Se
 nior Vice President of Translational Sciences\, Tranquis Therapeutics Inc
 .\, Jack Howden\, Senior Scientist\, MSD\, John Geisler\, Chief Scientifi
 c Officer\, Mitochon Pharmaceuticals\, Karin Westlund\, Professor\, Unive
 rsity of New Mexico Health Sciences Center\, Kira Mann\, Chief Executive 
 Officer\, MitoAction\, Krista Casazza\, Scientific Director\, PATH\, Lan 
 Wei-LaPierre\, Assistant Professor\, University of Florida\, Michal Mincz
 uk\, Cancer Research UK\, Senior Representative\, Agilent Technologies\, 
 Sophia Zilber\, Board Member\, Cure Mito foundation\, Tom Benson\, Chief 
 Executive Officer\, Mitrix Bio\n\nCategory:&nbsp\;Conferences | Science\,
  Health and Medicine | Pharmaceuticals\n\nDate and Time:&nbsp\;19th Novem
 ber 2024 at 9:00 am to 21st November 2024 at 5:00 pm\n\nVenue details:&nb
 sp\;Hilton Boston Back Bay\, 40 Dalton Street\, Boston\, Massachusetts\, 
 02115\, United States\n
DTEND:20241121T170000
DTSTAMP:20260512T223117Z
DTSTART:20241119T090000
LOCATION:Hilton Boston Back Bay\, 40\, Dalton Street\, Boston\, Massachuse
 tts\, 02115\,
SEQUENCE:0
SUMMARY:In light of Anavex's announcement of its first entire clinical gen
 e pathway data in patients with Rett syndrome\, coupled with Mission Ther
 apeutics'...
UID:68176df7-dffa-481a-8e01-55d404670c19
END:VEVENT
END:VCALENDAR